Aspen Expects Growth Following Sandoz And Viatris Deals
Reshaped Business Expects To See Significant Growth In First Half
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.
You may also be interested in...
South African’s Aspen Pharmacare has published first-half financials results that match a recent trading update, following a major reshaping. The new-look firm says it has “spent a long time building and a long time justifying building.”
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.